A judge in New York has rejected a proposed bankruptcy agreement between Purdue Pharma, the maker of the opioid Oxycontin, and myriad government agencies over provisions that would shield the Sackler family from future litigation. The settlement, which would put thousands of suits against the company to rest, has been years in the making but has encountered opposition from the U.S. Bankruptcy Trustee’s office and several state attorneys general in recent months due to the protections the family would receive. Under its current terms, the Sackler family will pay $4.5 billion, relinquish ownership of the company, and turn it into a charitable organization fighting addiction. The ruling is likely to be appealed by both Purdue and government agencies in favor of it.
Unlock a year of full access to The Daily Beast for $35.
Monthly
$1
First monththen $5.99/month
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $5.99 monthly. Cancel anytime
Annual
$35
First yearthen $59.99/year
Discounted annual rate - Save 47%
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $59.99 yearly. Cancel anytime
Best Value
Premium
$79
First yearthen $119.99/year
Discounted annual rate
Full access to the Daily Beast Substack ($60 value)*
Premium ad-free reading
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $119.99 yearly. Cancel anytime
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.
Subscription$0.00
Total$0.00
OR
Loading subscription options
Register below to read this article for free or subscribe to unlock unlimited access to The Daily Beast.
Monthly
$1
First monththen $5.99/month
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $5.99 monthly. Cancel anytime
Annual
$35
First yearthen $59.99/year
Discounted annual rate - Save 47%
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $59.99 yearly. Cancel anytime
Best Value
Premium
$79
First yearthen $119.99/year
Discounted annual rate
Full access to the Daily Beast Substack ($60 value)*
Premium ad-free reading
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $119.99 yearly. Cancel anytime
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.